Background: Development of topical microbicides and entry inhibitors is a promising approach to prevent sexually transmitted HIV infection. Mucosal dendritic cells (DCs) internalize HIV through DC-SIGN and, on arrival to lymphoid tissues, transmit the virus in trans to CD4 T lymphocytes, promoting HIV dissemination. DC-SIGN, thus, is a potential therapeutic target and the inhibition of HIV interaction with DC-SIGN may efficiently prevent the early stages of HIV infection. The DC-SIGN ligand is the HIV gp120 high mannose glycan Man9. We synthesized structural analogues of this glycan (using polyvalent presentations of di- and tri-mannoside mimics) in the attempt to compete with binding of DC-SIGN to HIV gp120. Methods: Different experimental models were designed: 1) inhibition of trans infection was assessed by using B-THP-1/ DC-SIGN cells. Ability of compounds to block lab and primary HIV-1 strains transmission to CD4 T cells was evaluated; 2) human endocervical explant tissues were treated with the compounds and then exposed to different HIV-1 strains in a non polarised manner. Infection was determined by measuring p24 levels in co-culture and in explant culture supernatants; 3) cytokines and chemokines production following stimulation of monocyte-derived DCs was analyzed. Toxicity of the compounds was evaluated in cellular and tissue models. Results: One of the compounds tested, a tetravalent dendron containing four copies of a linear trimannoside mimic (compound 12), almost completely (>98%) abrogated the transmission of R5- and X4-tropic HIV-1 lab strains and primary isolates to CD4 T cells at 100M. Notably the antiviral effect persisted up to 12 hours after compound removal. Compound 12 also prevented, in a dose-response manner, HIV-1 infection of human cervical tissues under conditions which mimic compromised epithelial integrity. Treatment with this compound significantly increased MIP-1 production as well. Toxicity of compound 12 was neglectable at the highest concentration tested in infection assay. Conclusion: Compound 12, a tetravalent dendron presenting trimannoside mimic, is endowed with a potent anti HIV activity independent of viral tropism. The activity is long-lasting and observed both when CD4 T lymphocytes or cervical explants are used. Competition with the binding of HIV to DC-SIGN and stimulation of MIP-1 production both contribute to such activity. This compound is potentially suitable for development as a vaginal microbicide.

A Glycomimetic compound inhibits DC-SIGN mediated HIV infection in cellular and cervical explant models / A. Berzi, S. Sattin, J.J. Reina Martin, M. Sanchez Navarro, J. Rojo, D. Trabattoni, P. Antonazzo, I. Cetin, A. Bernardi, M. Clerici. ((Intervento presentato al 3. convegno ICAR : Italian Conference on AIDS and Retroviruses tenutosi a Firenze nel 2011.

A Glycomimetic compound inhibits DC-SIGN mediated HIV infection in cellular and cervical explant models

A. Berzi
Primo
;
S. Sattin
Secondo
;
J.J. Reina Martin;D. Trabattoni;P. Antonazzo;I. Cetin;A. Bernardi
Penultimo
;
M. Clerici
Ultimo
2011

Abstract

Background: Development of topical microbicides and entry inhibitors is a promising approach to prevent sexually transmitted HIV infection. Mucosal dendritic cells (DCs) internalize HIV through DC-SIGN and, on arrival to lymphoid tissues, transmit the virus in trans to CD4 T lymphocytes, promoting HIV dissemination. DC-SIGN, thus, is a potential therapeutic target and the inhibition of HIV interaction with DC-SIGN may efficiently prevent the early stages of HIV infection. The DC-SIGN ligand is the HIV gp120 high mannose glycan Man9. We synthesized structural analogues of this glycan (using polyvalent presentations of di- and tri-mannoside mimics) in the attempt to compete with binding of DC-SIGN to HIV gp120. Methods: Different experimental models were designed: 1) inhibition of trans infection was assessed by using B-THP-1/ DC-SIGN cells. Ability of compounds to block lab and primary HIV-1 strains transmission to CD4 T cells was evaluated; 2) human endocervical explant tissues were treated with the compounds and then exposed to different HIV-1 strains in a non polarised manner. Infection was determined by measuring p24 levels in co-culture and in explant culture supernatants; 3) cytokines and chemokines production following stimulation of monocyte-derived DCs was analyzed. Toxicity of the compounds was evaluated in cellular and tissue models. Results: One of the compounds tested, a tetravalent dendron containing four copies of a linear trimannoside mimic (compound 12), almost completely (>98%) abrogated the transmission of R5- and X4-tropic HIV-1 lab strains and primary isolates to CD4 T cells at 100M. Notably the antiviral effect persisted up to 12 hours after compound removal. Compound 12 also prevented, in a dose-response manner, HIV-1 infection of human cervical tissues under conditions which mimic compromised epithelial integrity. Treatment with this compound significantly increased MIP-1 production as well. Toxicity of compound 12 was neglectable at the highest concentration tested in infection assay. Conclusion: Compound 12, a tetravalent dendron presenting trimannoside mimic, is endowed with a potent anti HIV activity independent of viral tropism. The activity is long-lasting and observed both when CD4 T lymphocytes or cervical explants are used. Competition with the binding of HIV to DC-SIGN and stimulation of MIP-1 production both contribute to such activity. This compound is potentially suitable for development as a vaginal microbicide.
Italian
28-mar-2011
HIV ; glycomimetic compounds ; DC-SIGN ; topical microbicides
Settore MED/04 - Patologia Generale
Settore CHIM/06 - Chimica Organica
Presentazione
Intervento inviato
Sì, ma tipo non specificato
ICAR : Italian Conference on AIDS and Retroviruses
Firenze
2011
3
Istituto Superiore di Sanità
Società Italiana di Virologia
Società Italiana di Virologia Medica
Convegno nazionale
A. Berzi, S. Sattin, J.J. Reina Martin, M. Sanchez Navarro, J. Rojo, D. Trabattoni, P. Antonazzo, I. Cetin, A. Bernardi, M. Clerici
A Glycomimetic compound inhibits DC-SIGN mediated HIV infection in cellular and cervical explant models / A. Berzi, S. Sattin, J.J. Reina Martin, M. Sanchez Navarro, J. Rojo, D. Trabattoni, P. Antonazzo, I. Cetin, A. Bernardi, M. Clerici. ((Intervento presentato al 3. convegno ICAR : Italian Conference on AIDS and Retroviruses tenutosi a Firenze nel 2011.
Prodotti della ricerca::14 - Intervento a convegno non pubblicato
info:eu-repo/semantics/conferenceObject
none
Conference Object
10
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/167120
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact